Clinical Trials Directory

Trials / Completed

CompletedNCT06004167

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

5-5-5 Adaptive Bridging Radiation Therapy (ABRT) for Relapsed/Refractory B-cell Lymphoma Prior to CAR T-cell Therapy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

Detailed description

This is a feasibility/pilot study of 5 Gy adaptive radiation administered every 5 business days (1 week apart) for 5 weeks prior to standard of care CAR T-cell therapy infusion. Approximately 10 participants with Relapsed/Refractory B-cell Lymphoma will take part in this research study. The primary objective is to assess the feasibility of once weekly radiation therapy for 5 weeks.

Conditions

Interventions

TypeNameDescription
RADIATIONAdaptive Bridging Radiation Therapy (ABRT)Radiation Therapy

Timeline

Start date
2024-01-14
Primary completion
2024-10-01
Completion
2024-12-01
First posted
2023-08-22
Last updated
2025-12-09

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06004167. Inclusion in this directory is not an endorsement.